

Studying the Effect of Anvirzel™, Carboplatin and Docetaxel Combination in NSCLC Cell Lines



Lung cancer is the leading cause of cancer-related mortality in both men and women. NSCLC accounts for approximately 85 % of all lung cancers. The aim of this study is to determine whether or not there is efficacy combining Anvirzel™, Carboplatin and Docetaxel in non-small cell lung cancer cell lines. Chemosensitivity-viability assays were performed in established human NSCLC cell lines for different incubation times and different densities of the three formulations. The results were time- and density-dependent. In 48h and 72h, optimal efficiency has been observed. The combination of the above compounds was more effective in the CALU-1 cancer cell line, and especially at lower densities. The combination of Anvirzel™, Carboplatin and Docetaxel seems to be more effective than monotherapy; while requiring low densities avoids dose-dependent toxicity.

Key words: Anvirzel™, Carboplatin, Docetaxel, viability assays, NSCLC

Nerium oleander (family Apocynaceae) is one of the most poisonous shrubs, because of its toxicity in all its parts^{1,2}. Oleandrin, which is a cardiac glycoside, is the most significant toxin of the plant, however it has been used in treatment of cardiac insufficiency, and many studies have demonstrated the potential effects on different types of cancer^{3,4,5}. Anvirzel™ is an extract of *Nerium oleander* that is mainly consist of Oleandrin and its derivative Oleandrogenin, and recent studies have pointed out its anti-cancer properties⁶. Carboplatin is a platinum-based chemotherapy drug, which is widely used against many carcinomas, due to its reduced side-effects compared with the primary cisplatin⁷. The combination with gemcitabine (GemCarbo chemotherapy), is commonly used in the treatment of lung cancer^{8,9}. Docetaxel is an anti-mitotic chemotherapy drug, mainly for the treatment of carcinomas after the failure of anthacycline-based chemotherapy. A lot of studies have proved that treatment with Carboplatin plus Docetaxel combination is safe and effective in patients with NSCLC^{10,11}. The present study aims to determine if there is efficacy in using an Anvirzel™-Carboplatin-Docetaxel combination, unlike single use of the above compounds, in human established non-small cell lung cancer cell lines. In order to determine the efficacy, chemosensitivity-viability assays, and especially methyl-tetrazolium dye (MTT), sulforhodamine B (SRB) and crystal violet staining (CVE) assays, have been used. MTT measures the activity of enzymes in mitochondria, as it is taken up through endocytosis by cells, and is metabolised by enzymes to formazan, giving a purple colour. Its main disadvantage is that it measures only the mitochondrial activity, thus is not a good factor to distinguish dead and alive cells. The measurements are time-dependent and are affected by pH

and glucose concentrations^{12,13,14,15}. The measurement of proteins has been used to overlap the deficiencies of the above assay. For the quantification of cellular proteins, SRB and CVE assays have been used. The first one is more sensitive to the detection of small numbers of cells with a linear relationship between SRB staining and cell number, and the absorption is not affected by pH^{16,17,18,19,20,21}. CVE binds electrostatically to proteins and stains DNA, and it may constitute an improving extension of MTT^{22,23}. All the assays are reliable, simple and reproducible.

Materials and Methods

Cell Lines

The study was performed in three established human non-small cell lung cancer cell lines, which were obtained by the ECACC (European Collection of Cell Cultures) from HPA (Health Protection Agency, UK). CALU-1, COLO699N and COR-L 105 cell lines have been tested. Cells were cultured as a monolayer in 75 cm² flasks (Orange Scientific, 5520200, Belgium) in the medium indicated for each line with the appropriate amount for each cell line of heat-inactivated fetal bovine serum (FBS, Invitrogen, 10106-169, California) and 2 mM L-glutamine (Sigma, G5792, Germany), and incubated at 37°C, in a 5 % CO₂ atmosphere. In CALU-1's medium non-essential amino acids (1 %) (Sigma, M7145, Germany) and sodium pyruvate (1 %) (Sigma, S8636, Germany) were also added.

Drugs

Anvirzel™ (Salud Integral, Honduras) was diluted in water, Docetaxel (Sigma, 01885, Germany) was diluted in N,N-Dimethylformamide (Fluka, 40255, Germany) and Carboplatin (Sigma, C2538, Germany) was diluted in deionised water. The densities that have been studied were from 0.01 ng/ml to 10 ng/ml for Anvirzel™, and from 0.01 µg/ml to 1 µg/ml for both Docetaxel and Carboplatin.

Viability Assays

Cells were detached by trypsinisation (Trypsin-0.25 % EDTA, Invitrogen, 25200-072, California) during the logarithmic phase of culture growth, and plated in 96-well plates (18,000 cells/well) (Corning, Costar 359, USA) in a final volume of 200 µl of medium per well. After 70-80 % confluence of the culture, the medium was removed and drugs individually and in all possible combinations were added to cells. The absorbance was measured after 24h, 48h and 72h of incubation.

The 96-well plates were fixed by 10 % TCA-trichloroacetic acid (Fluka, 91228, Germany), and were incubated at 4°C for 1h for an SRB assay. Afterwards, plates were rinsed with water and cells were stained with 0.4 % SRB (Sigma, 341738,

Germany), dissolved in 1 % acetic acid (Carlo Ebra, 401422, Italy) for 15 min at room temperature (RT). The unbound stain was washed twice with 1 % acetic acid. Ultimately, 10mM Tris Buffer pH 10.5 (Sigma, T6791, Germany) was added, in order to dissolve the dye.

In the CVE protocol, the medium was removed from the 96-well plates, the plates were rinsed with PBS (Sigma, P3813, Germany) and then the cells were rinsed by the addition of 10 % formalin (Merck, 1.04003.2500, USA) for 20 min at RT. Formalin was removed, and 0.25 % aqueous crystal violet (Sigma, HT901, Germany) dissolved in water, was added for 10 min at RT. Unbound crystal violet was rinsed by washing with water, and finally 33 % acetic acid was dissolved the dye.

Finally, for the MTT assay, methyl-tetrazolium dye (Sigma, M2128, Germany), in a density of 5mg/ml (diluted in PBS) was added to each well, and plates were incubated for 3h at 37°C. After the incubation, the medium was discarded and the cells were rinsed with PBS. Ultimately, the formazan crystals were dissolved in dimethylsulphoxide (Sigma, D4540, Germany). The calculation of absorbance measurements was given in the Beer-Lambert law, where the formula is $A = \epsilon \cdot c \cdot l$. "A" is the absorbance, "ε" is an extinction coefficient of the absorber, "l" is the distance the light travels through the material, and "c" is the concentration of absorbing species in material.

The plate's optical density was measured on the μQuant spectrophotometer and the data were analysed with Gen5 software (μQuant Biomolecular Spectrophotometer MQX200 and Gen5™ Microplate Data Collection & Analysis software, BioTek® Instruments, Inc, April 2008). Absorbance was measured at 570nm for all the assays, and a second wavelength was measured in order to subtract the noise. For the MTT assay, the value of additional wavelength was 630nm and for SRB and CVE assay was 690nm.

Statistical Analysis

All treatments for each cell line were performed in triplicate, three times. The statistical significance of all effects was evaluated by "difference of the means" test ($p < 0.05$).

Table 1: Statistic evaluation of absorbance in CALU-1 cell line.

CALU-1 Cell Line ABSORBANCE		
CVE Assay	48h	72h
Unstimulated cells	1,052	2,097
0.01 ng/ml Anvirezol	0,948	2,005
0.1 ug/ml Carboplatin	1,019	2,27
0.1 ug/ml Docetaxel	0,366	0,386
0.01 ng/ml Anvirezol + 0.1 ug/ml Carboplatin + 0.1 ug/ml Docetaxel	0,297 ($p=0,0004<0,05$)	0,114 ($p=0,0001<0,05$)
MTT Assay	48h	72h
Unstimulated cells	0,549	1,131
0.01 ng/ml Anvirezol	0,626	1,025
0.1 ug/ml Carboplatin	0,518	1,047
0.1 ug/ml Docetaxel	0,137	0,084
0.01 ng/ml Anvirezol + 0.1 ug/ml Carboplatin + 0.1 ug/ml Docetaxel	0,108 ($p=0,008<0,05$)	0,056 ($p=0,001<0,05$)
SRB Assay	48h	72h
Unstimulated cells	2,587	2,843
0.01 ng/ml Anvirezol	2,59	2,804
0.1 ug/ml Carboplatin	2,624	2,938
0.1 ug/ml Docetaxel	1,564	1,727
0.01 ng/ml Anvirezol + 0.1 ug/ml Carboplatin + 0.1 ug/ml Docetaxel	1,516 ($p=0,0004<0,05$)	1,003 ($p=0,0009<0,05$)

Results

The results that were obtained were different for each cancer cell line, demonstrating once again the heterogeneity of carcinomas, even in the same type of cancer. The combination of Anvirezol™-Carboplatin-Docetaxel, affected the CALU-1 cell line more, and the rest less. The results were time- and density-dependent. After 24h of incubation, efficacy was observed almost nowhere due to the above combination, as well as due to the single use of each compound. The optimum results were obtained at lower densities of Anvirezol™ and at densities less than 1 ug/ml for the other drugs at 48 and 72 hours of incubation. Specifically, in CALU-1 cell line the combination of 0.01 ng/ml of Anvirezol™ with 0.1 ug/ml of Carboplatin and 0.1 ug/ml of Docetaxel decreased the cells null up to 95 %. There was also an observed reduction of the population in higher densities of Carboplatin and

Chart 1: Reduction percentage in CALU-1 cancer cell line for CVE Assay




Chart 2: Reduction percentage in CALU-1 cancer cell line for SRB Assay





Chart 3: Reduction percentage in CALU-1 cancer cell line for MTT Assay



Docetaxel; however the percentage was up to 85%. In the COLO699N cell line it has been observed that the more effective combination is the one with the lower densities (0.01 ng/ml Anvritel™, 0.01 ug/ml Carboplatin and 0.01 ug/ml Docetaxel). The lowest efficacy, both of combination and individual use, was observed in the COR-L 105 cancer cell line. Also in this cell line, the combination of 0.01 ng/ml of Anvritel™ with 0.1 ug/ml of Carboplatin and 0.1 ug/ml of Docetaxel was optimal, and decreased the cells null up to 65%. The schedule (Table 1) and following diagrams (Diagrams 1-3) illustrate the chemosensitivity-viability assays results.

Discussion

Anvritel™ is a compound extracted from *Nerium oleander*, and mainly consists of polysaccharides, proteins and two cardiac glycosides, Oleandrin and its derivative Oleandrogenin. As cardiac glycosides, they inhibit the Na⁺/K⁺-ATPase and are able to inhibit proliferation of tumour cells through high concentrations of intracellular calcium^{5,25}. Other studies have demonstrated that Oleandrin suppresses the activation of many transcription factors and also enhances the radio-sensitivity of tumours^{26,27,28}. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5²⁹. Oleandrin induces cell death through activation of caspases in a variety of human tumour cells, but also activates calcineurin and NF-AT via FasL³⁰. Anvritel™ interacts with the membrane Na⁺/K⁺-ATPase pump in prostate cell lines and thus inhibits the FGF-2 export³¹.

Carboplatin as an alkylating agent interacts with DNA. Although it is less potent than Cisplatin, it has the main advantage of reduced side-effects. It is used in combination with Paclitaxel, or with Docetaxel for treatment of NSCLC^{32,33}.

Docetaxel belong to the chemotherapy drug class taxane, and is an anti-mitotic drug which binds to microtubules and stabilises them³⁴. It is an analogue of paclitaxel, having a hydroxyl functional group on carbon 10 and a tert-butyl carbamate ester, whereas paclitaxel has an acetate ester and a benzyl amide respectively¹⁰. Docetaxel plus Carboplatin is effective as a second-line treatment in patients with advanced non-small cell lung cancer³².

Methyl-tetrazolium dye, sulforhodamine B and crystal violet staining assays were performed to evaluate the combination of the three above formulations in established NSCLC cell lines. The panel of the three different assays has been used to ensure reliable and repeatable results.

The CALU-1 cell line was the one in which the combination was more effective, even at low densities. It is well known that Anvritel™ has better efficacy at densities from 0.01 ng/ml to 1 ng/ml. In the particular cell line, the optimal densities were 0.01-1 ng/ml of Anvritel™, 0.1 ug/ml of Carboplatin and 0.1 ug/ml of Docetaxel. This combination reduces the cell number up to 95% after 72 hours of incubations, whereas the monotherapy reached a lower rate. In the COLO699N and COR-L105 cell lines, lower reduction percentages were observed, which, however, were observed at the same density range. The effect was time-dependent, as its effects have not been observed after 24 hours of incubation, but only after 48, and especially 72, hours of incubation.

Conclusion

The present study has proved that the combination of Anvritel™-Carboplatin-Docetaxel is more effective than monotherapy in different NSCLC cell lines. The remarkable thing is that the above combination has better efficacy at low densities of the three formulations, thus preventing the toxicity of chemotherapy. There is an urgent need for further studies to be done that will reveal and assess the interaction of extracted substances with established chemotherapy drugs.

Acknowledgements

The authors thank two anonymous referees who made useful comments that improved the manuscript.



Panagiotis Apostolou graduated from the Department of Molecular Biology and Genetics, Democritus University of Thrace, in 2007. Since October 2008 I have been working in the research and development department of the R.G.C.C. (Research Genetic Cancer Center Ltd, www.rgcc-genlab.com), and I am active in the field of molecular biology. Email: apostolou.panagiotis@rgcc-genlab.com



Maria Toloudi studied molecular biology and genetics in the University of Thrace and now I have been working for about three years in the R.G.C.C as a member of the research and development department. I am active especially in the field of cellular and molecular biology dealing with human cancer stem cells. Email: toloudi.maria@rgcc-genlab.com



Marina Chatziioannou was born and grew up in Greece. I studied biochemistry and biotechnology at the University of Thessaly (2001-2006). I have worked at the R.G.C.C. laboratory since 2006, at the clinical department, flow cytometry section. I mainly work on Human Circulating Tumour Cells (CTCs). Email: chatziioannou.marina@rgcc-genlab.com



Ioannis Papisotiriou was born in Germany in 1973 and returned in childhood to Greece, where I studied in the Medical School of Thessaloniki, specialising in human genetics in Switzerland. Two master degree awards have been obtained in molecular biology in medicine from Westminster University (UK), and in oncology from the University of Nottingham (UK). I was promoted to MD in MLU in Germany under the field of evaluation of TKIs in human cancer cell lines. Since 2004 I have been the director and founder of RGCC Ltd, which is active in both areas of service (research and clinical). Email: papisotiriou.ioannis@rgcc-genlab.com

References:

1. Shaw, D. & Pearn, J. Oleander poisoning. *Med J Aust* 2, 267-269 (1979).
2. Mahin, L., Marzou, A. & Huart, A. A case report of Nerium oleander poisoning in cattle. *Vet Hum Toxicol* 26, 303-304 (1984).
3. Newman, R. A. et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. *Integr Cancer Ther* 6, 354-364 (2007).
4. Felth, J. et al. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. *J Nat Prod* 72, 1969-1974 (2009).
5. Yang, P. et al. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. *Mol Cancer Ther* 8, 2319-2328 (2009).
6. Wang, X., Plomley, J. B., Newman, R. A. & Cisneros, A. LC/MS/MS analyses of an oleander extract for cancer treatment. *Anal Chem* 72, 3547-3552 (2000).
7. Wheate, N. J., Walker, S., Craig, G. E. & Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. *Dalton Trans* 39, 8113-8127, doi:10.1039/c0dt00292e (2010).
8. Miyahara, E. et al. [Combination of carboplatin and gemcitabine is a safe and feasible regimen in adjuvant therapy for stage II and IIIA NSCLC]. *Gan To Kagaku Ryoho* 35, 483-485 (2008).
9. Murialdo, R. et al. Gemcitabine and carboplatin treatment in advanced NSCLC: a retrospective evaluation including elderly patients. *Tumori* 95, 36-42 (2009).
10. Clarke, S. J. & Rivory, L. P. Clinical pharmacokinetics of docetaxel. *Clin Pharmacokinet* 36, 99-114 (1999).
11. Baker, S. D., Sparreboom, A. & Verweij, J. Clinical pharmacokinetics of docetaxel : recent developments. *Clin Pharmacokinet* 45, 235-252, doi:4532 [pii] (2006).
12. Sargent, J. M. The use of the MTT assay to study drug resistance in fresh tumour samples. *Recent Results Cancer Res* 161, 13-25 (2003).
13. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 65, 55-63, doi:0022-1759(83)90303-4 [pii] (1983).
14. Twentyman PR, L. M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. *Br J Cancer* 56, 279-285 (1987).
15. Liu, Y., Peterson, D. A., Kimura, H. & Schubert, D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. *J Neurochem* 69, 581-593 (1997).
16. Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 82, 1107-1112 (1990).
17. Voigt, W. Sulforhodamine B assay and chemosensitivity. *Methods Mol Med* 110, 39-48 (2005).
18. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protoc* 1, 1112-1116 (2006).
19. Keepers, Y. P. et al. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. *Eur J Cancer* 27, 897-900 (1991).
20. Fricker, S. P. The application of sulforhodamine B as a colorimetric endpoint in a cytotoxicity assay. *Toxicol In Vitro* 8, 821-822 (1994).
21. Haselsberger, K., Peterson, D. C., Thomas, D. G. & Darling, J. L. Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. *Anticancer Drugs* 7, 331-338 (1996).
22. Ishiyama, M. et al. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. *Biol Pharm Bull* 19, 1518-1520 (1996).
23. Chiba, K., Kawakami, K. & Tohyama, K. Simultaneous evaluation of cell viability by neutral red, MTT and crystal violet staining assays of the same cells. *Toxicol In Vitro* 12, 251-258 (1998).
24. Ingle, JDJ & Crouch, SR: *Spectrochemical Analysis*. New Jersey: Prentice Hall, 1988.
25. McConkey, D. J., Lin, Y., Nutt, L. K., Ozel, H. Z. & Newman, R. A. Cardiac glycosides stimulate Ca²⁺ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. *Cancer Res* 60, 3807-3812 (2000).
26. Manna, S. K., Sah, N. K., Newman, R. A., Cisneros, A. & Aggarwal, B. B. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. *Cancer Res* 60, 3838-3847 (2000).
27. Sreenivasan, Y., Sarkar, A. & Manna, S. K. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. *Biochem Pharmacol* 66, 2223-2239, doi:S0006295203006191 [pii] (2003).
28. Nasu, S., Milas, L., Kawabe, S., Raju, U. & Newman, R. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. *Cancer Lett* 185, 145-151, doi:S030438350200263X [pii] (2002).
29. Frese S, F.-S. M., Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. *Cancer Res* 66, 5867-5874 (2006).
30. Raghavendra, P. B., Sreenivasan, Y., Ramesh, G. T. & Manna, S. K. Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. *Apoptosis* 12, 307-318, doi:10.1007/s10495-006-0626-3 (2007).
31. Smith, J. A., Madden, T., Vijjeswarapu, M. & Newman, R. A. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. *Biochem Pharmacol* 62, 469-472, doi:S0006-2952(01)00690-6 [pii] (2001).
32. Wachters, F. M., van Putten, J. W., Boezen, H. M. & Groen, H. J. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. *Lung Cancer* 45, 255-262 (2004).
33. Bando, H., Miyata, J., Sano, T. & Sumitomo, M. [Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC)]. *Gan To Kagaku Ryoho* 28, 947-952 (2001).
34. Tabaczar, S., Koceva-Chyla, A., Matczak, K. & Gwozdziński, K. [Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules]. *Postepy Hig Med Dosw (Online)* 64, 568-581(2010).